Glen Eagle Advisors’s BioNTech BNTX Stock Holding History

Glen Eagle Advisors’s Portfolio BNTX Stock Details BNTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$9.3K	Hold	100	–	–	﹤0.01%	717
2026 Q1	$8.89K	Hold	100	–	–	﹤0.01%	689
2025 Q4	$9.52K	Hold	100	–	–	﹤0.01%	699
2025 Q3	$9.86K	Hold	100	–	–	﹤0.01%	697
2025 Q2	$10.6K	Hold	100	–	–	﹤0.01%	639
2025 Q1	$9.11K	Hold	100	–	–	﹤0.01%	656
2024 Q4	$11.4K	Hold	100	–	–	﹤0.01%	631
2024 Q3	$11.9K	Hold	100	–	–	﹤0.01%	635
2024 Q2	$8.04K	Hold	100	–	–	﹤0.01%	685
2024 Q1	$9.22K	Hold	100	–	–	﹤0.01%	670
2023 Q4	$10.6K	Hold	100	–	–	﹤0.01%	626
2023 Q3	$10.9K	Hold	100	–	–	﹤0.01%	621
2023 Q2	$10.8K	Hold	100	–	–	﹤0.01%	623
2023 Q1	$12.5K	Hold	100	–	–	﹤0.01%	585
2022 Q4	$15K	Hold	100	–	–	﹤0.01%	535
2022 Q3	$13.5K	Hold	100	–	–	﹤0.01%	546
2022 Q2	$14.9K	Hold	100	–	–	﹤0.01%	557
2022 Q1	$17.1K	Hold	100	–	–	﹤0.01%	536
2021 Q4	$25.8K	Hold	100	–	–	0.01%	472
2021 Q3	$27.3K	Hold	100	–	–	0.01%	491
2021 Q2	$22.4K	Hold	100	–	–	0.01%	535
2021 Q1	$10.9K	Hold	100	–	–	﹤0.01%	650
2020 Q4	$8.15K	Buy	+100	New	+$9.82K	﹤0.01%	663

Other funds holding BNTX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Flossbach Von Storch Cologne, Germany $22.1B AUM 6.81% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

GSK plc London $602M AUM

Glen Eagle Advisors's BNTX Position: Q2 2026 in Review

Glen Eagle Advisors held its BioNTech (BNTX) position steady in Q2 2026 at 100 shares worth $9.3K. The position accounts for ﹤0.01% of the portfolio, ranked #717.

Glen Eagle Advisors first reported a position in BNTX in Q4 2020 and has held it in 23 quarters since. The position peaked at $27.3K in Q3 2021. 283 funds tracked by Wall St. Rank hold BNTX as of Q2 2026.

Glen Eagle Advisors held 100 shares of BioNTech worth $9.3K as of Q2 2026.
Glen Eagle Advisors left its BioNTech share count unchanged in Q2 2026.
BioNTech made up ﹤0.01% of Glen Eagle Advisors's portfolio in Q2 2026, its #717 holding.
Glen Eagle Advisors first reported a position in BioNTech in Q4 2020 and has held it in 23 quarters since.
Glen Eagle Advisors's BioNTech position peaked at $27.3K in Q3 2021.
283 funds tracked by Wall St. Rank held BioNTech as of Q2 2026.

Based on Glen Eagle Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.